Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Income Statements
Fiscal Year end for Jazz Pharmaceuticals PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3,834 | 3,659 | 3,094 | 2,364 | 2,162 |
Cost Of Goods | 436 | 541 | 441 | 149 | 128 |
Gross Profit | 3,399 | 3,119 | 2,653 | 2,215 | 2,034 |
Selling & Adminstrative & Depr. & Amort Expenses | 2,820 | 3,184 | 2,483 | 1,837 | 1,501 |
Income After Depreciation & Amortization | 579 | -66 | 170 | 378 | 532 |
Non-Operating Income | 9 | -19 | -4 | -3 | -6 |
Interest Expense | 289 | 288 | 279 | 100 | 72 |
Pretax Income | 298 | -373 | -113 | 275 | 454 |
Income Taxes | -120 | -159 | 216 | 34 | -73 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | -3 | -10 | -1 | -3 | -4 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 415 | -224 | -330 | 239 | 523 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 415 | -224 | -330 | 239 | 523 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,217 | 564 | 723 | 713 | 949 |
Depreciation & Amortization (Cash Flow) | 639 | 629 | 552 | 335 | 417 |
Income After Depreciation & Amortization | 579 | -66 | 170 | 378 | 532 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 72.07 | 62.54 | 59.69 | 56.52 | 57.55 |
Diluted EPS Before Non-Recurring Items | 15.76 | 10.75 | 14.18 | 10.77 | 14.60 |
Diluted Net EPS (GAAP) | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 |
Fiscal Year end for Jazz Pharmaceuticals PLC falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 1,023.83 | 901.98 | 1,011.94 | 972.14 | 957.32 |
Cost Of Goods | 109.90 | 95.49 | 107.24 | 102.15 | 97.54 |
Gross Profit | 913.92 | 806.50 | 904.69 | 869.99 | 859.78 |
SG&A, R&D, and Dept/Amort Expenses | 714.47 | 740.29 | 782.19 | 697.59 | 702.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | 199.45 | 66.21 | 122.50 | 172.40 | 157.64 |
Non-Operating Income | 0.51 | -1.69 | 9.35 | -1.38 | -2.38 |
Interest Expense | 62.02 | 66.12 | 70.32 | 71.50 | 73.47 |
Pretax Income | 137.93 | -1.60 | 61.53 | 99.52 | 81.78 |
Income Taxes | -30.65 | 11.67 | -33.09 | -47.18 | -24.32 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | -0.01 | -1.35 | -0.46 | 0.13 | -1.67 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 168.57 | -14.62 | 94.15 | 146.82 | 104.44 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 168.57 | -14.62 | 94.15 | 146.82 | 104.44 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 69.63 | 62.54 | 69.67 | 71.29 | 73.54 |
Diluted EPS Before Non-Recurring Items | 4.67 | 1.98 | 4.40 | 4.22 | 3.83 |
Diluted Net EPS (GAAP) | 2.49 | -0.23 | 1.40 | 2.14 | 1.52 |